Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

QUETIAPINE

All products: not a benefit

Other products in the same Health Canada class (N05A, N05AH) — coverage varies; not interchangeable

  • Asenapine (Saphris): general benefit
  • Loxapine (Loxapac): general benefit, Not a benefit
  • Olanzapine (Zyprexa Zydis): general benefit, Not a benefit
  • Clozapine (AA-Clozapine Tablet): not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Quetiapine Tablets · DIN 02387816 · 150mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Quetiapine Tablets · DIN 02387816 Manufacturer: Accord Healthcare Inc.; listing date 2012-08-27 Health Canada: Marketed since 2024-04-03 · brand ACH-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 150 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87339 · Verify on the e-Formulary ↗ (DIN 02387816)

Source record
DIN 02387816: Quetiapine Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608209; group id 506; item number 1323; lccId None; manufacturer id ACH Source form: Tab; strength: 150mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3518; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387816 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87339
Interchangeable products
Seroquel · DIN 02240862 · not recorded Teva-Quetiapine · DIN 02284251 · not recorded
Shortage status: resolved shortage (ended 2026-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387816
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

CLOZAPINE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 200mg, 25mg, 100mg ·

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the manifestations of schizophrenia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE LURASIDONE HYDROCHLORIDE · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) INDICATIONS AND CLINICAL USE Adults Schizophrenia Taro-Lurasidone (lurasidone hydrochloride tablets) is indicated for the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00065650.PDF; date not captured; DIN 02504499; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DECANOATE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230406; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DIHYDROCHLORIDE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230402; fetched 2026-09-10 Product monograph • the management of the manifestations of schizophrenia. CLOPIXOL (zuclopenthixol tablets as zuclopenthixol hydrochloride) may be used during initial treatment and for maintenance treatment. CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) is intended for the initial treatment of acute psychotic episodes or exacerbation of psychosis associated with schizophrenia. CLOPIXOL DEPOT (zuclopenthixol decanoate injection) is intended for maintenance treatment. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230402; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. INDICATIONS Schizophrenia SEROQUEL (quetiapine fumarate immediate-release) is indicated for: • the management of the manifestations of schizophrenia. The antipsychotic efficacy of SEROQUEL was established in short-term (6-week) controlled inpatient trials (see 14 CLINICAL TRIALS). The efficacy of SEROQUEL in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials of patients with manifestations of schizophrenia. Bipolar Disorder SEROQUEL is indicated as monotherapy for the: • acute management of manic episodes associated with bipolar disorder. • acute management of depressive episodes associated with bipolar I and bipolar II disorder. The efficacy of SEROQUEL in bipolar mania was established in two 12-week clinical trials of bipolar patients (see 14 CLINICAL TRIALS). The safety and effectiveness of SEROQUEL for long-term use, and for prophylactic use in bipolar mania has not been evaluated. The efficacy of SEROQUEL in bipolar depression was established in four 8-week clinical trials that included either bipolar I or bipolar II patients (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the … https://pdf.hres.ca/dpd_pm/00078929.PDF PM date: MAR 18, 2025 Source product: SEROQUEL; DIN 02236951; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Quetiapine Tablets: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026